The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The initiative includes academic and private sector partners and aims to train new researchers in the early diagnosis of brain cancer.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
